請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49538
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李繼忠 | |
dc.contributor.author | I-Chen Chu | en |
dc.contributor.author | 朱怡甄 | zh_TW |
dc.date.accessioned | 2021-06-15T11:33:38Z | - |
dc.date.available | 2019-09-08 | |
dc.date.copyright | 2016-09-08 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-16 | |
dc.identifier.citation | 1. Barbieri, F., Thellung, S., Ratto, A., et al. (2015). In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. BMC Cancer, 15, 228.
2. Bianchi, C., Penno, G., Romero, F., et al. (2007). Treating the metabolic syndrome. Expert Rev Cardiovasc Ther, 5(3), 491-506. 3. Bowker, S. L., Majumdar, S. R., Veugelers, P., et al. (2006). Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 29(2), 254-258. 4. Chu, I. P. (2015). Clinical Trial of Intratumoral Injecting Anti-tumorigenic Factors to Skin Tumors of Canines (Master), National Taiwan University, Taipei. 5. Dizeyi, N., Bjartell, A., Nilsson, E., et al. (2004). Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate, 59(3), 328-336. 6. Dovizio, M., Tacconelli, S., Sostres, C., et al. (2012). Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel), 5(12), 1346-1371. 7. Eisenhauer, E. A., Therasse, P., Bogaerts, J., et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45(2), 228-247. 8. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., et al. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330(7503), 1304-1305. 9. Gallagher, E. J., & LeRoith, D. (2011). Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci, 1243, 54-68. 10. Goldberg, E. P., Hadba, A. R., Almond, B. A., et al. (2002). Intratumoral cancer chemotherapy and immunotherapy- opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol, 54(2), 159-180. 11. Goldschmidt, M., Dunstan, R. A., Von, T. C., et al. (1998). Histological Classification of Epithelial and Melanocytic Tumors of the Skin of Domestic Animals. (2 ed.). Washington: Armed Forces Institute of Pathology: Armed Forces Institute of Pathology. 12. Grier, R. L., Brewer, W. G., Jr., & Theilen, G. H. (1980). Hyperthermic treatment of superficial tumors in cats and dogs. J Am Vet Med Assoc, 177(3), 227-233. 13. Hanif, R., Pittas, A., Feng, Y., et al. (1996). Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol, 52(2), 237-245. 14. Hasan, J. A., & Memon, G. U. (2005). Impact of metformin therapy in patients with polycystic ovarian syndrome. J Coll Physicians Surg Pak, 15(11), 712-715. 15. Kato, K., Gong, J., Iwama, H., et al. (2012). The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther, 11(3), 549-560. 16. Lammers, T., Peschke, P., Kuhnlein, R., et al. (2006). Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia, 8(10), 788-795. 17. Landman, G. W., Kleefstra, N., van Hateren, K. J., et al. (2010). Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care, 33(2), 322-326. 18. Li, D. (2011). Metformin as an antitumor agent in cancer prevention and treatment. J Diabetes, 3(4), 320-327. 19. Liu, W., MacKay, J. A., Dreher, M. R., et al. (2010). Injectable intratumoral depot of thermally responsive polypeptide-radionuclide conjugates delays tumor progression in a mouse model. J Control Release, 144(1), 2-9. 20. Lubbe, A. S., & Huhnt, W. (1994). Microvessel diameters of human colon adenocarcinoma during acute treatment with serotonin. Int J Microcirc Clin Exp, 14(4), 218-225. 21. Luo, Q., Hu, D., Hu, S., et al. (2012). In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer, 12, 517. 22. Martin-Castillo, B., Vazquez-Martin, A., Oliveras-Ferraros, C., et al. (2010). Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle, 9(6), 1057-1064. 23. Neel, J. A., Snyder, L., & Grindem, C. B. (2012). Thrombocytosis: a retrospective study of 165 dogs. Vet Clin Pathol, 41(2), 216-222. 24. Nelson, R., Spann, D., Elliott, D., et al. (2004). Evaluation of the oral antihyperglycemic drug metformin in normal and diabetic cats. J Vet Intern Med, 18(1), 18-24. 25. Nielsen, S. W., & Attosmis, J. (1964). CANINE PERIANAL GLAND TUMORS. J Am Vet Med Assoc, 144, 127-135. 26. Noto, H., Goto, A., Tsujimoto, T., et al. (2012). Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One, 7(3), e33411. 27. Palm, C. A., & Feldman, E. C. (2013). Oral hypoglycemics in cats with diabetes mellitus. Vet Clin North Am Small Anim Pract, 43(2), 407-415. 28. Pereira, R. S., Schweigert, A., Dias de Melo, G., et al. (2013). Ki-67 labeling in canine perianal glands neoplasms: a novel approach for immunohistological diagnostic and prognostic. BMC Vet Res, 9, 83. 29. Plumb, D. C. (2015). Plumb's veterinary drug handbook (Eighth edition. ed.). Stockholm, Wisconsin Ames, Iowa: PharmaVet Inc. Distributed by John Wiley & Sons. 30. Pulito, C., Sanli, T., Rana, P., et al. (2013). Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention. Metabolites, 3(4), 1051-1075. 31. Rayburn, E. R., Ezell, S. J., & Zhang, R. (2009). Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol, 1(1), 29-43. 32. Russell, W. O., Cohen, J., Enzinger, F., et al. (1977). A Clinical and Pathological Staging System for Soft Tissue Sarcomas. Cancer, 40(4), 1562-1570. 33. Saeki, K., Watanabe, M., Tsuboi, M., et al. (2015). Anti-tumour effect of metformin in canine mammary gland tumour cells. Vet J, 205(2), 297-304. 34. Sahra, I. B., Marchand-Brustel, Y. L., Tanti, J. F., et al. (2010). Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther, 9(5), 1092-1099. 35. Salpeter, S. R., Greyber, E., Pasternak, G. A., et al. (2003). Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med, 163(21), 2594-2602. 36. Sarrouilhe, D., Clarhaut, J., Defamie, N., et al. (2015). Serotonin and cancer: what is the link? Curr Mol Med, 15(1), 62-77. 37. Sasaki, H., Asanuma, H., Fujita, M., et al. (2009). Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation, 119(19), 2568-2577. 38. Sheen, Y. J., & Sheu, W. H. (2012). Links among type 2 diabetes, cancer and metformin use: what have we learned? Diabetes Res Clin Pract, 97(2), 169-171. 39. Siddiqui, E. J., Shabbir, M. A., Mikhailidis, D. P., et al. (2006). The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. BJU Int, 97(3), 634-639. 40. Soll, C., Riener, M. O., Oberkofler, C. E., et al. (2012). Expression of serotonin receptors in human hepatocellular cancer. Clin Cancer Res, 18(21), 5902-5910. 41. Spugnini, E. P., Dotsinsky, I., Mudrov, N., et al. (2007). Biphasic pulses enhance bleomycin efficacy in a spontaneous canine perianal tumors model. J Exp Clin Cancer Res, 26(4), 483-487. 42. Sternbach, H. (1991). The serotonin syndrome. Am J Psychiatry, 148(6), 705-713. 43. Tozon, N., Kodre, V., Sersa, G., et al. (2005). Effective treatment of perianal tumors in dogs with electrochemotherapy. Anticancer Res, 25(2a), 839-845. 44. Turek, M. M., & Withrow, S. J. (2013). Perianal Tumors. In S. Withrow, D. Vail, & R. Page (Eds.), Withrow and MacEwen's Small Animal Clinical Oncology (5th ed., pp. 423-431). St. Louis: Saunders. 45. Veterinary cooperative oncology group. (2011). Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 46. Vicaut, E., Laemmel, E., & Stucker, O. (2000). Impact of serotonin on tumour growth. Ann Med, 32(3), 187-194. 47. Wang, D., & Dubois, R. N. (2006). Prostaglandins and cancer. Gut, 55(1), 115-122. 48. Wypij, J. M. (2015). Pilot study of oral metformin in cancer-bearing cats. Vet Comp Oncol. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49538 | - |
dc.description.abstract | 近年來許多研究專注於研發新穎的癌症治療方式,此研究中使用的藥物TD-B10為一種小分子藥物的複合型藥劑,其成分包括每福敏、阿斯匹靈及血清素。主要成分每福敏為一種二甲雙胍類降血糖藥物,目前在人類醫學上被廣泛使用於第二型糖尿病的治療,其被證實可以活化AMPK路徑並抑制mTOR,可抑制肝臟的糖質新生作用,並且有控制蛋白質生成和細胞增生的效果,另外,由腫瘤壞死因子引起的壞死也是TD-B10重要的抗癌機制。
本雙盲試驗之目標為確認腫瘤內注射TD-B10於犬隻圍肛腺瘤之治療效果、安全性及適用性。經由組織病理切片確診為圍肛腺瘤之犬隻根據良惡性、腫瘤分級分層,並隨機分配至藥物組和安慰劑組,於連續兩週的週一至週五,每日一次,共進行十劑注射,治療後連續四週進行追蹤。主要試驗終點為治療後四週的治療反應率及腫瘤消退率。 共26隻犬隻完成試驗,包含藥物組14隻和安慰劑組12隻。藥物組的平均腫瘤消退率(45.16 ± 42.87%)優於安慰劑組(-6.15 ± 45.64%),達統計上顯著差異(P=0.0168),另外,藥物組的平均治療反應率為57.14%(8/14; 2 CR, 6 PR),顯著優於安慰劑組8.33%(1/12; 1 PR)(P=0.0145)。在考量多種因素下,包含病畜之品種、腫瘤體積、臨床分級等,藥物組的治療效果仍顯著優於安慰劑組。依據獸醫癌症協會,多數副作用為一至二級,常見的副作用包含注射區域反應、疼痛及消化道症狀,少數藥物組病畜出現三級注射區域反應,認為和藥物造成之腫瘤壞死及脫落有關。 本研究結果顯示,TD-B10腫瘤內注射對於犬隻圍肛腺瘤有顯著的抗腫瘤效果,並能有效地造成腫瘤消退。 | zh_TW |
dc.description.abstract | TD-B10 is a formula composite of which the principal component is metformin, a biguanide hypoglycemic agents for type 2 diabetes treatment. Metformin is known to have antineoplastic activity by activating the AMPK/mTOR pathway. Necrosis induced by tumor necrosis factor (TNF) is also considered an important part in the TD-B10 antitumor activity.
The aim of this study is to determine the treatment efficacy in canine perianal gland tumors also the safety and feasibility of TD-B10 intratumoral injection in small animal cancer patients. Dogs with histopathologically confirmed perianal gland tumors are stratified and randomly divided into two groups. The tumors will receive either TD-B10 injection or placebo control once daily on weekdays for two consecutive weeks for total of 10 injections. The primary end point is the response rate and the tumor regression rate at the end of the 4-weeks follow-up period. A total of 26 dogs were recruited. The tumor regression rate in treatment group (n=14) was 45.16 ± 42.87% compared with -6.15 ± 45.64% for placebo group (n=12) (P=0.0168). The objective response rate in treatment group was 57.14% (8/14; 2 CR, 6 PR) compared with 8.33% (1/12; 1 PR) for placebo group (P=0.0145). The tumor regression rate of TD-B10 group was higher than the placebo group despite the patients’ breed, tumor volume, clinical stage and multiple factors. The toxicities were mostly limited to grade I to II where injection site reactions, pain and gastrointestinal toxicities were most commonly observed. The result of this study demonstrated that TD-B10 has significant anti-tumor activity and can evoke tumor regression in canine perianal tumors. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T11:33:38Z (GMT). No. of bitstreams: 1 ntu-105-R02643019-1.pdf: 16641657 bytes, checksum: fe4a1778c64e188c6f21919f1b0bd426 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員會審定書 #
致謝 i 摘要 ii Abstract iii Contents v List of Tables vii List of Figures viii Chapter I Introduction 1 Chapter II Literature Review 5 2.1 Intratumoral injection 6 2.2 TD-B10 formulation 7 2.2.1 Metformin 7 2.2.1.1 Metformin and cancer 8 2.2.1.2 Anticancer mechanisms of metformin 10 2.2.1.3 Metformin in veterinary oncology 11 2.2.2 Serotonin 12 2.2.2.1 Serotonin and cancer 13 2.2.3 Aspirin 14 2.2.3.1 Aspirin and cancer 15 2.3 Pilot study of TD-B10 16 2.4 Perianal gland tumors 16 2.4.1 Treatment of perianal gland tumors 18 Chapter III Materials and Methods 20 3.1 Study material 21 3.2 Study design 21 3.2.1 Patient selection 22 3.2.2 Baseline evaluation 23 3.2.3 Treatment protocol 24 3.2.4 Clinical assessment and monitoring 25 3.3 Assessment of tumor response 26 3.4 Assessment of adverse effect 27 3.5 Primary end point 28 3.6 Statistical analysis 28 Chapter IV Results 32 4.1 Patient population 33 4.1.1 Patient characteristics 33 4.1.2 Tumor type and clinical staging 34 4.1.3 Treatment group 34 4.2 Overall response 36 4.2.1 Treatment response in caliper measurement 36 4.2.2 Treatment response in ultrasound and CT measurement 37 4.3 Effectiveness and influence factors evaluation in caliper measurement 38 4.3.1 Regression analysis of tumor regression rate 38 4.3.2 Age 39 4.3.3 Gender and neuter status 40 4.3.4 Breed 42 4.3.5 Tumor volume 42 4.3.6 Clinical stage 43 4.3.7 Histopathological type 44 4.3.8 Ratio of tumor volume and injection volume 46 4.4 Safety and toxicity 47 4.4.1 Adverse events 47 4.4.2 Tumor assessment 49 4.4.3 Laboratory examination 50 4.5 Patients follow-up 53 Chapter V Discussion 54 5.1 Patient population and tumor type 55 5.2 Tumor measurement 55 5.3 Overall response 58 5.4 Effectiveness and influence factors 59 5.5 Safety and toxicity 61 5.6 Limitation 65 5.7 Future Prospects 66 Chapter VI Conclusion 69 Reference 71 Tables 75 Figures 86 | |
dc.language.iso | en | |
dc.title | 評估犬隻圍肛腺瘤接受腫瘤內注射藥物TD-B10之療效--多試驗中心、雙盲、隨機分組、安慰劑對照試驗 | zh_TW |
dc.title | A Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Intratumoral Injection TD-B10 in Dogs with Perianal Gland Tumors | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林辰栖,廖泰慶,李雅珍 | |
dc.subject.keyword | 每福敏,阿斯匹靈,血清素,腫瘤內注射,犬隻圍肛腺瘤, | zh_TW |
dc.subject.keyword | metformin,aspirin,serotonin,intratumoral injection,canine perianal gland tumor, | en |
dc.relation.page | 90 | |
dc.identifier.doi | 10.6342/NTU201602553 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-17 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 臨床動物醫學研究所 | zh_TW |
顯示於系所單位: | 臨床動物醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 16.25 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。